Why Are Nearly Two-Thirds of Alzheimer’s Patients Women? The Answer Goes Beyond Living Longer.

For decades, the explanation was simple: women live longer. But scientists are uncovering a more complicated story involving estrogen, menopause, genetics, an unexpected vaccine, and emerging research into creatine and brain-protective peptides.

Picture lunch with three girlfriends you’ve known for 25 years.

Somewhere between discussing the kids, aging parents, questionable wardrobe decisions and the restaurant’s increasingly ambitious prices, someone forgets the name of an actor. You know, the one. From the thing. With the hair. Another admits she walked into the kitchen that morning and forgot why. A third says she’s started writing absolutely everything down because she no longer trusts her brain to remember an appointment.

Everyone laughs. “Menopause brain,” someone declares, and the conversation moves on.

Usually, these moments are exactly what they appear to be: ordinary lapses, distracted moments, or some of the cognitive annoyances that accompany hormonal changes, interrupted sleep and a life involving approximately 400 competing responsibilities. But there’s another conversation about women’s brains that deserves considerably more attention, and it begins with a statistic that’s difficult to ignore.

Nearly two-thirds of Americans living with Alzheimer’s disease are women.

According to the Alzheimer’s Association’s 2026 figures, approximately 4.5 million women aged 65 and older are living with Alzheimer’s dementia in the United States, compared with 2.9 million men. At age 65, a woman’s estimated remaining lifetime risk is approximately 1 in 5, compared with 1 in 9 for men.

For decades, the explanation centered on one fairly straightforward fact: women tend to live longer, and Alzheimer’s becomes dramatically more common with advancing age. That explanation is important, but researchers are now investigating whether something else may be happening long before the first symptoms appear. Specifically, whether the female brain undergoes biological changes during midlife that could influence its vulnerability decades later.

And one of the most intriguing areas of investigation isn’t old age at all. It’s menopause.

First, a statistic that needs a little unpacking

Before we blame estrogen for everything—and goodness knows it already has quite a workload—we need to distinguish between two questions that sound similar but mean very different things. How many women are living with Alzheimer’s? And are women more likely than men of the same age to develop it?

Imagine two groups of people with identical chances of developing a disease at every age. If one group lives several years longer, that group will accumulate more cases simply because more of its members survive into the years when the disease becomes common. That’s a substantial part of the Alzheimer’s picture, and most American studies comparing women and men of the same age have not found a large, consistent difference in how frequently new Alzheimer’s or dementia cases develop.

So the headline statistic doesn’t mean that every woman has nearly twice the biological risk of the man standing next to her. Women account for a larger proportion of people living with Alzheimer’s and face a higher estimated lifetime probability of developing it, in significant part because they live longer.

But longevity may not explain every difference researchers are observing. Scientists have identified sex-related differences in Alzheimer’s-associated brain changes, genetic susceptibility and certain patterns of disease progression. Some of these findings raise the possibility that the biological processes influencing neurological aging may begin shifting years, even decades, before someone receives a diagnosis.

Which brings us to a hormone most women have already spent a considerable amount of their lives negotiating with.

Your brain has been paying attention to estrogen all along

We usually discuss estrogen in connection with menstrual cycles, fertility, hot flashes and the mystery of why the bedroom suddenly feels like a tropical greenhouse at 2 a.m. But estrogen isn’t exclusively a reproductive hormone. The brain contains estrogen receptors, and estrogen participates in a remarkable range of neurological processes, including communication between neurons, glucose metabolism and the formation and maintenance of connections involved in learning and memory.

Think of your brain as a city with an enormous electricity bill. Every conversation, memory, decision and movement depends on billions of nerve cells communicating through a network that consumes tremendous amounts of energy. Estrogen doesn’t operate the entire power grid, but it participates in regulating parts of that system, influencing how certain cells use fuel and respond to changing conditions.

During the reproductive years, the brain becomes accustomed to a hormonal environment in which estrogen rises and falls through recurring cycles. Then perimenopause arrives, and the schedule becomes considerably less predictable. Estrogen levels can fluctuate dramatically before eventually settling at much lower levels after menopause. Meanwhile, the brain has to adapt to this changing environment while continuing its usual responsibilities: remembering names, finding car keys, managing complicated relationships and deciding whether replying to one particular email is worth ruining an otherwise pleasant afternoon.

It’s a remarkable amount of adaptation, and researchers have begun asking what those adjustments actually look like inside the brain. That’s where the story becomes considerably more interesting than the familiar conversation about hot flashes and brain fog.

What researchers found when they looked inside the midlife brain

Neuroscientist Dr. Lisa Mosconi and her colleagues have spent years examining how the menopause transition relates to neurological aging, using brain-imaging technologies that can measure much more than memory performance alone.

In a 2017 study published in Neurology, researchers examined 42 cognitively healthy women between 40 and 60, comparing women at different menopausal stages with 18 similarly aged men. Their scans measured brain structure, glucose metabolism and deposits of beta-amyloid, a protein associated with Alzheimer’s disease. Compared with premenopausal women and men, women in perimenopause and postmenopause showed lower glucose metabolism in certain regions, differences in brain tissue volume and higher amyloid measurements.

What makes these findings particularly intriguing is that the women were cognitively healthy. They weren’t patients presenting with dementia or obvious neurological impairment. They were functioning normally, and yet researchers could identify biological differences associated with their menopausal stage. Subsequent imaging research has continued exploring how these changes evolve over time, including whether the brain develops compensatory adaptations as the hormonal environment changes.

Before anyone begins imagining that menopause is quietly dismantling their brain, however, an important distinction deserves emphasis. A change in glucose metabolism isn’t the same as cognitive decline, and an amyloid measurement doesn’t predict with certainty whether a particular woman will develop Alzheimer’s. These were relatively small observational studies, and they cannot establish that menopause causes the disease.

Nevertheless, the findings suggest something worth investigating: the neurological transition associated with menopause may involve measurable changes in the brain’s energy use and other processes long before clinical problems become apparent. Whether those changes increase Alzheimer’s vulnerability, represent normal adaptation, or involve some combination of the two remains an open scientific question.

The brain fog problem: when normal starts feeling suspicious

For many women, this subject feels personal long before they’ve read a neurological study. Perimenopause can bring an irritating collection of cognitive complaints: losing your train of thought, struggling to retrieve an ordinary word, or walking into a room only to discover that the reason for going there has apparently left without you. It can feel as though your brain has 37 browser tabs open, three are playing music, and you have absolutely no idea which ones.

Researchers take these experiences seriously, even though brain fog isn’t a formal medical diagnosis. Studies following women through menopause have identified small but measurable changes in certain types of memory and cognitive performance that aren’t explained entirely by chronological aging.

Here’s the reassuring part: for nearly all women, cognitive performance remains within normal limits. Experiencing brain fog during perimenopause doesn’t mean you’re developing Alzheimer’s, any more than occasionally forgetting your reading glasses means you’re developing a progressive neurological disorder.

There’s also the matter of everything else happening during midlife. Interrupted sleep, hot flashes, anxiety, depression, medications and thyroid conditions can all interfere with concentration and memory. Sometimes what feels like forgetting is actually a problem with attention. If you set down your keys while answering a text, carrying groceries and mentally organizing dinner, your brain may never have properly registered where you put them. It’s difficult to retrieve a memory that wasn’t successfully stored in the first place.

Persistent, progressive or disruptive cognitive symptoms deserve medical attention, particularly when they begin interfering with everyday life. But ordinary menopausal brain fog and Alzheimer’s disease are not interchangeable, and treating them as though they are would turn a common experience into an unnecessary source of fear.

Two proteins, one complicated story

To understand why scientists are investigating differences between women’s and men’s brains, we need to meet two proteins that appear repeatedly in Alzheimer’s research: amyloid-beta and tau.

Amyloid-beta is a peptide that can accumulate into plaques between nerve cells, while tau normally helps stabilize structures within neurons. In Alzheimer’s disease, abnormal forms of tau build up into tangles inside cells, disrupting systems that help neurons function.

Imagine a city in which garbage collection is becoming less efficient while important roads and rail lines are deteriorating. The trouble isn’t simply that waste is accumulating. It’s that the systems responsible for maintenance, communication and transportation are beginning to fail together. Alzheimer’s involves a similarly complicated collection of processes, including abnormal protein accumulation, inflammation, cellular damage and eventually the loss of functioning neural connections.

Researchers are especially interested in whether women and men differ in how these changes develop. A study using data from the Framingham Heart Study examined 328 cognitively normal adults and found that women showed higher tau measurements in certain brain regions than men. Menopausal status also appeared relevant to some findings, particularly when amyloid was present.

These observations suggest hormonal status could influence aspects of Alzheimer’s-related pathology, although they don’t establish causation or predict an individual’s future. Estrogen may be part of the explanation, but genetics, immune function and other biological differences are also being investigated.

And genetics introduces an especially interesting complication.

The genetic wildcard: APOE4

APOE is a gene involved in producing a protein that transports cholesterol and other fats through the body, including the brain. One common version, APOE4, is associated with a higher risk of late-onset Alzheimer’s disease, although carrying it certainly doesn’t mean a person is destined to develop dementia.

Many APOE4 carriers never develop Alzheimer’s, and plenty of people without the variant do. But researchers have found evidence that the relationship between APOE4 and Alzheimer’s risk may differ between women and men at certain ages, making it an especially interesting area of investigation during midlife.

A 2026 study involving 145 midlife women examined differences in brain activity and connectivity during a verbal-memory task. Women carrying APOE4 showed different patterns of brain activation and communication, even though researchers didn’t detect corresponding differences in actual task performance or the Alzheimer’s blood biomarkers measured.

Think about what that means. Researchers could observe differences in how the brain was performing a task without finding evidence that the women were performing it any worse.

That doesn’t mean these participants were beginning to develop Alzheimer’s. It suggests that the brain can adjust its activity in ways imaging technologies detect long before those differences necessarily translate into noticeable problems—if they ever do. It’s another reminder that neurological aging isn’t simply a matter of things gradually shutting down. The brain adapts, compensates and reorganizes, sometimes in ways scientists are only beginning to understand.

So should women take estrogen to protect their brains?

At this point, there’s an obvious question. If estrogen influences brain metabolism, neuronal communication and memory-related processes, and estrogen declines around menopause, wouldn’t replacing it help protect against Alzheimer’s?

It’s an attractive theory, and there’s enough biological reasoning behind it that researchers have investigated it extensively. Unfortunately, what makes sense at the molecular level doesn’t always translate into the clinical outcome everyone hopes for.

Some observational studies have reported lower rates of Alzheimer’s or dementia among women who used hormone therapy, particularly certain estrogen-based treatments begun around midlife. But randomized trials involving women who started particular hormone regimens at age 65 or older found an increased risk of dementia, especially with the estrogen-plus-progestogen combinations studied.

Why the apparent contradiction? Timing may matter, since beginning hormone therapy shortly after menopause isn’t biologically equivalent to beginning it 15 or 20 years later. Formulation matters too: oral conjugated estrogens differ from transdermal estradiol, and different progestogens have different biological properties. Observational research also has a persistent difficulty in separating the effects of treatment from the characteristics of women who choose to receive it, including healthcare access, exercise habits and underlying health.

The study that complicates everything

The KEEPS Cognitive and Affective Study investigated hormone therapy in 693 recently postmenopausal women, comparing oral estrogen with progesterone, transdermal estradiol with progesterone, and placebo. Researchers evaluated cognition and mood over approximately four years, looking for changes that might clarify whether beginning treatment near menopause influenced neurological function.

The results weren’t what enthusiasts of the brain-protection theory might have hoped. Neither hormone-treatment group showed a significant improvement in cognition compared with placebo, although one regimen produced benefits in certain mood-related measures.

Researchers later revisited a subset of participants approximately a decade after the original trial. Once again, women originally assigned to hormone therapy performed similarly on cognitive testing to those who received placebo. This was reassuring regarding the long-term cognitive outcomes of the studied regimens in that population, but it didn’t demonstrate that early hormone treatment provided lasting protection against decline.

The distinction is important: estrogen can play a substantial role in brain biology without estrogen replacement automatically preventing Alzheimer’s disease. Hormone therapy may offer meaningful benefits for menopausal symptoms, but current evidence doesn’t justify prescribing it solely to prevent dementia.

That doesn’t make estrogen unimportant to the brain. It means we’ve learned that understanding a biological mechanism and developing an effective preventive treatment are two very different accomplishments.

The unexpected directions Alzheimer’s research is taking

If hormone research teaches us anything, it’s that Alzheimer’s is unlikely to be explained—or solved—by a single biological pathway. Scientists are now investigating everything from viral infections and immune responses to cellular energy systems and specialized signaling peptides.

Some of these ideas have produced intriguing human results. Others remain largely laboratory research. And a few have already encountered the sort of disappointing clinical trials that remind us why plausible theories need to be tested.

The shingles vaccine twist

One of the most surprising dementia findings in recent years came from a vaccine originally developed for an entirely different problem.

In 2013, Wales introduced a shingles vaccination program with a particularly strict birthday cutoff. People born on or after September 2, 1933, were eligible, while those born just before that date weren’t. It sounds like an administrative technicality, but it created an unusually valuable opportunity for researchers.

People born just days apart are likely to be similar in age and many other characteristics, yet their eligibility for vaccination differed dramatically. By comparing outcomes around this cutoff, researchers could investigate the vaccine’s possible effects while reducing some of the biases that complicate ordinary observational studies.

The analysis included health records from more than 280,000 older adults. Over approximately seven years, the researchers estimated that receiving the shingles vaccine was associated with a 20% relative reduction in new dementia diagnoses. Even more intriguingly for our discussion, the estimated effect was stronger among women than men.

The researchers couldn’t establish exactly why vaccination might influence dementia risk. One possibility involves the varicella-zoster virus, which causes chickenpox and can reactivate later in life as shingles. Because this virus remains dormant in the nervous system, preventing reactivation could potentially reduce certain neurological or inflammatory effects. Other explanations involve the immune system’s response to vaccination itself.

An important detail is that the Welsh study examined the older live-attenuated shingles vaccine, Zostavax, rather than the recombinant Shingrix vaccine currently recommended in the United States. Further research is needed to determine whether different formulations have similar effects and whether vaccination directly reduces dementia risk.

Still, it’s a fascinating discovery. An intervention designed to prevent a painful viral illness may ultimately teach researchers something important about immunity and the aging brain, including why neurological disease develops differently in women and men.

Creatine: not just for gym bros anymore

Creatine has spent decades associated with weight rooms, protein shakes and people who enjoy discussing their deadlift numbers. Now it’s attracting attention for something considerably less obvious: the brain’s ability to manage energy.

Your brain is an extraordinarily demanding organ. Maintaining electrical activity, transporting signals and sustaining neural connections requires a dependable supply of ATP, the molecule cells use as an immediate energy source. Creatine participates in a system that helps regenerate ATP, acting as a rapid energy buffer when cellular demand increases.

We’ve known for years that this system matters in muscle. But neurons also depend on tightly regulated energy supplies, and Alzheimer’s disease involves disturbances in brain metabolism that may contribute to impaired cellular function.

That led researchers to an intriguing question: could creatine supplementation help support energy metabolism in people already experiencing Alzheimer’s disease?

In 2025, investigators at the University of Kansas Medical Center conducted a small pilot involving 20 patients with Alzheimer’s disease. Participants received creatine monohydrate over eight weeks while researchers measured brain creatine levels and changes in cognitive performance.

Brain creatine increased by approximately 11%, and participants improved on several cognitive tests, including measures related to attention and working memory. Those are encouraging observations, particularly because they suggest supplementation can measurably change brain creatine levels under the conditions studied.

But there’s a significant limitation: the study had no placebo group. With only 20 participants and no comparison group, researchers cannot tell how much of the apparent cognitive improvement resulted from creatine rather than repeated testing, expectations or other influences. The study also used a relatively high daily amount under research supervision, so its protocol shouldn’t be treated as a general recommendation.

Creatine isn’t a proven Alzheimer’s treatment, and we don’t know whether it prevents dementia or slows disease progression. But its established role in cellular energy metabolism makes it a reasonable candidate for further investigation, especially as researchers examine how energy disturbances contribute to neurological decline.

It’s rather wonderful that a supplement most people associate with building muscle might also help researchers understand the energy requirements of an aging brain.

What about peptides? A different approach to brain protection

Here’s a detail that surprises people who primarily associate peptides with metabolism, skincare or longevity treatments: amyloid-beta, one of the central molecules in Alzheimer’s research, is itself a peptide.

Of course, that doesn’t mean peptides are inherently beneficial or harmful. They’re simply chains of amino acids, and their biological effects depend on their structure and function. Some participate in normal signaling, while others, under particular conditions, contribute to disease.

Researchers have become increasingly interested in therapeutic peptides because these molecules can influence specific biological pathways. In Alzheimer’s research, that has encouraged investigations into metabolic signaling, inflammation, neuronal survival and the cellular systems responsible for managing damage.

A few directions are particularly intriguing, although their levels of evidence differ substantially.

GLP-1 medications: an exciting theory meets a major reality check

GLP-1 medications became famous for treating diabetes and obesity, but researchers began exploring their potential neurological effects well before the current enthusiasm surrounding weight-loss drugs.

GLP-1 is a peptide hormone involved in metabolic regulation, and drugs acting on its receptor can influence insulin-related pathways and other processes relevant to brain health. Because Alzheimer’s disease involves changes in energy metabolism, inflammation and cellular function, scientists wondered whether these medicines could offer benefits beyond blood glucose and body weight.

Early laboratory findings, observational studies and smaller clinical investigations created considerable interest. A trial of liraglutide, an older GLP-1 medication, reported potentially encouraging effects on certain measures of brain atrophy and cognition, although the evidence wasn’t sufficient to establish a meaningful treatment benefit.

Then researchers tested the idea on a much larger scale.

In November 2025, Novo Nordisk announced results from EVOKE and EVOKE+, two phase 3 trials involving 3,808 people with early symptomatic Alzheimer’s disease. Participants received oral semaglutide or placebo alongside standard care, allowing investigators to examine whether the medication slowed clinical disease progression.

It didn’t. Although certain Alzheimer’s-related biomarkers improved, semaglutide did not significantly slow clinical progression compared with placebo.

That’s a disappointing result, but an enormously important one. Improving a biological marker doesn’t necessarily mean improving memory, preserving independence or altering the course of dementia. A treatment can influence pathways associated with Alzheimer’s without producing the clinical benefits researchers hope for.

The GLP-1 story isn’t necessarily finished. Scientists may investigate other medications, earlier disease stages or different treatment approaches. But the large negative trials mean we cannot treat the class as an established Alzheimer’s therapy simply because the underlying biology is appealing.

Intranasal insulin: could the nose offer another route to the brain?

Insulin is another peptide hormone with an intriguing connection to neurological function. Although most of us associate it with blood sugar, insulin also participates in signaling within the brain, and disturbances in those pathways have been observed in Alzheimer’s disease.

This relationship has led some researchers to use the phrase type 3 diabetes when discussing Alzheimer’s. It’s a provocative analogy, not an official medical diagnosis, and Alzheimer’s is certainly not simply diabetes of the brain. But it reflects growing interest in the relationship between insulin signaling, energy metabolism and neurodegeneration.

One experimental approach involves administering insulin through the nose, using anatomical pathways that may allow certain substances to reach the central nervous system while limiting some effects elsewhere in the body.

Early studies produced encouraging observations, but larger clinical investigations have not established consistent cognitive benefits. Differences in delivery devices, formulations and study populations have complicated the results, leaving researchers with more questions than answers.

Nevertheless, intranasal insulin illustrates something important about the direction of neurological research. Rather than focusing exclusively on amyloid plaques, scientists are also investigating whether improving the brain’s metabolic environment could influence disease processes.

Humanin and MOTS-c: messages from your mitochondria

Of all the emerging peptide research, this one has a particularly interesting origin story.

In 2001, scientists studying Alzheimer’s disease investigated genetic material associated with brain tissue that had survived despite surrounding pathology. Their work led to the identification of Humanin, a small peptide associated with mitochondrial genetic sequences that demonstrated protective effects against certain types of Alzheimer’s-related cellular injury in laboratory experiments.

Mitochondria, as everyone who survived high-school biology may remember, are commonly introduced as the powerhouses of the cell. That’s accurate as far as it goes, but it rather understates their job description.

Beyond producing cellular energy, mitochondria participate in signaling, stress responses and processes that influence whether damaged cells survive. Researchers have also identified small peptides encoded by mitochondrial DNA, opening an entirely new field of investigation into how these structures communicate with the rest of the cell and body.

Humanin attracted particular attention because laboratory experiments suggested it could protect neurons against certain damaging processes associated with Alzheimer’s biology. That doesn’t mean it has been shown to prevent dementia in people, but the discovery introduced a fascinating possibility: mitochondria may produce signaling molecules involved in cellular protection and adaptation.

Another mitochondrial-derived peptide, MOTS-c, has attracted interest for its roles in metabolic regulation and responses to cellular stress. We’ve previously explored MOTS-c in September Wellness, particularly its relationship to mitochondrial function and aging research.

The distinction is that Humanin has a more direct historical connection to Alzheimer’s-related laboratory investigations, while MOTS-c has been studied more broadly in metabolism and aging biology. Neither has demonstrated clinical effectiveness for preventing or treating Alzheimer’s disease.

Still, the emergence of mitochondrial-derived peptides is one of the more intriguing developments in cellular biology. These structures aren’t merely supplying energy to neurons; they may also participate in molecular conversations about stress, survival and repair.

For a disease involving profound disturbances in cellular function, that’s a conversation worth understanding.

Semax and the possibility of supporting neuroplasticity

Our recent September Wellness article on Semax and Selank explored two Russian-developed peptides associated with different neurological research traditions. Semax has been investigated particularly in relation to stroke recovery and mechanisms involved in neuronal adaptation, while Selank has been studied more extensively for anxiety-related effects.

Some animal research on Semax has demonstrated changes in BDNF, a protein involved in neuronal survival and the brain’s ability to strengthen and reorganize connections. Because Alzheimer’s ultimately damages those connections, it’s understandable that researchers would be interested in compounds that might influence neuroplasticity.

But there’s a considerable distance between observing changes in BDNF signaling and demonstrating that a treatment prevents neurodegeneration. Semax has not been established through adequate human clinical trials as a treatment for Alzheimer’s, and the anxiety research surrounding Selank doesn’t provide evidence that it prevents dementia.

What makes these compounds scientifically interesting is their potential to help researchers investigate different aspects of neural regulation. They aren’t interchangeable with metabolic peptides or mitochondrial-derived molecules, and their possible biological effects shouldn’t be lumped together simply because they share the word peptide.

The broader lesson is that future neurological treatments may work through several different pathways. Some may target amyloid or tau directly, while others investigate inflammation, cellular metabolism, immune signaling or the brain’s ability to adapt to damage.

It’s entirely possible that peptides will contribute to some of those strategies. But at present, many of the compounds attracting attention in longevity discussions remain closer to experimental possibilities than established clinical treatments.

The part of brain health we’re overlooking

There’s something a little frustrating about how we discuss Alzheimer’s prevention. We devote enormous attention to finding the one gene, hormone, supplement or investigational compound that might determine our neurological future, while some of the strongest opportunities for improving long-term brain health involve things we’ve understood for years.

Blood pressure. Cholesterol. Physical activity. Hearing. Smoking. Diabetes. Social connection.

Admittedly, nobody is likely to build a luxury wellness retreat around checking your blood pressure. Yet the evidence linking cardiovascular and metabolic health with cognitive outcomes deserves at least as much attention as the more glamorous possibilities emerging from laboratories.

The 2024 Lancet Commission on dementia identified 14 potentially modifiable risk factors and estimated that addressing them could prevent or delay approximately 45% of dementia cases at the population level. That isn’t a guarantee that any individual can avoid dementia through lifestyle choices, and it certainly doesn’t suggest that people who develop the disease somehow failed to take care of themselves. It’s an estimate of how much population-level disease burden might potentially be reduced through prevention and improved healthcare.

For women, the menopause transition makes this discussion especially relevant. Midlife often brings changes in sleep, body composition, cholesterol, blood pressure and glucose regulation, all while hormonal fluctuations introduce an additional layer of complexity. Many of these factors can be addressed, even as scientists continue investigating their precise connections to Alzheimer’s disease.

Your brain is an organ with an enormous appetite for oxygen, energy and reliable circulation. Protecting the systems that supply those resources may not sound as exciting as a new peptide discovered in mitochondrial DNA, but it remains an important part of the bigger picture.

And the encouraging thing is that the two approaches aren’t mutually exclusive. We can take established prevention research seriously while remaining genuinely curious about what the next generation of neurological science might discover.

Maybe the biggest change is when we start paying attention

For much of the twentieth century, Alzheimer’s was discussed primarily as a disease of old age, which makes sense given that symptoms usually become apparent later in life. But neuroscience has increasingly demonstrated that biological changes associated with the disease can begin many years before a diagnosis.

For women, menopause provides an especially interesting opportunity to investigate those earlier changes. It’s a major, identifiable hormonal transition occurring during decades when cardiovascular health, metabolism, sleep and other important systems may also be shifting. Researchers can study how those changes interact, whether certain genetic profiles influence the brain’s response, and why some women show more Alzheimer’s-related pathology while others remain cognitively healthy throughout their lives.

The emerging work on viral immunity adds another possible dimension, as do investigations into mitochondrial function, creatine and specialized peptides involved in cellular signaling. Not every promising idea will survive rigorous clinical testing, and some already haven’t. But the expanding range of research questions reflects a more sophisticated understanding of Alzheimer’s as a complex disease involving multiple interacting systems.

Importantly, none of this means a woman approaching menopause should imagine her brain as a countdown clock toward dementia. That would be scientifically unjustified and a spectacularly unhelpful way to spend the next 30 years.

What has changed is not that menopause has suddenly become something to fear. It’s that scientists are taking a period of women’s neurological lives seriously, asking questions that historically received far too little attention, and discovering that the biology of brain aging may be considerably more interesting than we once imagined.

And perhaps the biggest advance won’t come from one miracle treatment at all, but from learning how to recognize risk earlier, understand the different pathways involved, and eventually match interventions to the people most likely to benefit.

Your brain has a long future ahead. The goal isn’t simply to keep it young, but to give it the best possible chance to age well.

Do This Week

1. Take brain fog seriously, but not catastrophically.

Notice whether your difficulties involve concentration, word-finding, poor sleep or meaningful memory changes. Menopause-related cognitive complaints are common and generally don’t indicate dementia, but persistent, worsening or disruptive symptoms deserve evaluation.

2. Know your numbers.

Blood pressure, cholesterol and blood sugar aren’t just cardiovascular concerns. They’re relevant to brain health, too. If you haven’t reviewed them recently, make an appointment with your healthcare professional.

3. Ask about the shingles vaccine.

If you’re 50 or older and haven’t received the recommended shingles vaccine, ask whether you’re eligible. Its established purpose is preventing shingles, while the emerging dementia research is an intriguing possibility rather than a proven additional benefit.

4. Protect your sleep rather than accepting exhaustion as normal.

Hot flashes, insomnia and repeated awakenings can seriously affect concentration and everyday functioning. Effective treatment may improve your quality of life even though better sleep cannot guarantee protection from Alzheimer’s.

5. Put movement on the brain-health agenda.

Walking, strength training and other regular physical activity support cardiovascular and metabolic health. You don’t need a complicated neurological fitness program; you need a sustainable routine that challenges your body and fits your life.

6. Have a proper menopause conversation.

If you’re considering hormone therapy, discuss your symptoms, age, medical history and individual risks with a knowledgeable clinician. Treatment may provide meaningful relief for certain menopausal symptoms, but it shouldn’t be presented as proven Alzheimer’s prevention.

This article is intended for educational purposes and does not replace individualized medical advice. Alzheimer’s disease and other forms of dementia have multiple risk factors, and research into menopause, hormones, supplements, peptides and neurological aging is ongoing. Experimental compounds discussed here have not been established as treatments for preventing or treating Alzheimer’s disease. New, persistent or worsening cognitive symptoms should be evaluated by a qualified healthcare professional. Sudden confusion or other acute neurological symptoms require emergency evaluation.

Sources & Further Reading

1. Alzheimer’s Association. 2026 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 2026.

The comprehensive annual report providing U.S. Alzheimer’s prevalence figures, lifetime-risk estimates and information about differences between women and men.

2. Mosconi L, Berti V, Quinn C, et al. Sex Differences in Alzheimer Risk: Brain Imaging of Endocrine vs Chronologic Aging. Neurology, 2017.

Brain-imaging research examining menopause, glucose metabolism, brain structure and amyloid biomarkers in cognitively healthy adults.

3. Buckley RF, O’Donnell A, McGrath ER, et al. Menopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study. Annals of Neurology, 2022.

Research investigating differences in tau accumulation between women and men and the possible influence of menopausal status.

4. Gleason CE, Dowling NM, Kara F, et al. Long-Term Cognitive Effects of Menopausal Hormone Therapy: Findings From the KEEPS Continuation Study. PLOS Medicine, 2024.

Long-term follow-up examining cognitive outcomes among women originally assigned to menopausal hormone therapy or placebo.

5. Eyting M, Xie M, Michalik F, et al. A Natural Experiment on the Effect of Herpes Zoster Vaccination on Dementia. Nature, 2025.

A large Welsh natural experiment reporting fewer dementia diagnoses associated with receiving the older shingles vaccine, with stronger estimated effects among women.

6. Smith AN, Choi I-Y, Lee P, et al. Creatine Monohydrate Pilot in Alzheimer’s: Feasibility, Brain Creatine, and Cognition. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2025.

An eight-week study of 20 people with Alzheimer’s disease, reporting increased brain creatine and improvements in cognitive testing. The study had no placebo group, so clinical benefits remain unproven.

7. Novo Nordisk. Evoke Phase 3 Trials Did Not Demonstrate a Statistically Significant Reduction in Alzheimer’s Disease Progression. Company clinical trial announcement, November 2025.

Results from two large randomized trials involving 3,808 participants, in which oral semaglutide did not significantly slow Alzheimer’s progression.

8. Lee C, Yen K, Cohen P. Humanin: A Harbinger of Mitochondrial-Derived Peptides? Trends in Endocrinology & Metabolism, 2013.

A scientific review examining Humanin’s discovery, its possible neuroprotective mechanisms and the emerging biology of mitochondrial-derived peptides.

9. Livingston G, Huntley J, Liu KY, et al. Dementia Prevention, Intervention, and Care: 2024 Report of the Lancet Standing Commission. The Lancet, 2024.

A comprehensive review identifying 14 potentially modifiable dementia risk factors and examining opportunities for prevention across the lifespan.